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Abstract
Influenza presents a significant risk for increased morbidity and mortality to pregnant
women and infants based on evidence from previous influenza pandemics, seasonal
epidemics,  and the recent H1N1 pandemic. Since 2004, influenza vaccine has been
recommended for pregnant women during any trimester of pregnancy to reduce this
risk. This chapter presents an overview of influenza risks associated with pregnancy
as well as a review of our current understanding of vaccine effectiveness in pregnant
women, neonates,  and young infants.  In addition,  some of the current compelling
questions related to influenza risk and prevention across all trimesters of pregnancy
are explored.
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1. Introduction
Influenza is a highly contagious, acute respiratory infection (ARI). Each year, it is estimated
that 5–10% of adults and 20–30% of children worldwide will become infected with influenza
[1].  Pregnant  women and infants  are  at  particular  risk for  influenza.  Influenza infection
during pregnancy or during the first 6 months of life is a substantial cause of morbidity.
Prevention of influenza in these populations is of global health importance.
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2. Maternal influenza
Pregnant women are considered a high-risk group for serious illness and complications from
influenza. While annual influenza incidence rates in pregnant women are similar to those of
nonpregnant women [2–4], influenza infection is associated with increased morbidity and
mortality in this subpopulation, with pregnant women having an increased risk of influenza-
attributed hospitalizations compared to nonpregnant women [4, 5]. Most likely this is associ-
ated with the interaction of the infection with the physiologic and immunologic changes that
occur during pregnancy.
Pregnancy-associated changes such as decreased lung capacity, reduced tidal volume, and
increased cardiac output likely reduce the capacity of the respiratory and cardiac system to
respond to the stress of influenza infection [2, 6]. In addition, during pregnancy there is a
progressive suppression of cellular (T-cell mediated) immunity. While this immune suppres-
sion serves to protect the developing fetus from maternal cytotoxic T-cell immunity, it can
impair the maternal response to viral infections such as influenza [7–11].
The combination of these factors contributes to an increased risk of negative outcomes from
influenza infection. If respiratory disease develops, especially during the later stages of
pregnancy, it can lead to high morbidity among the pregnant women [6, 12–14]. In a study of
hospital admissions records of women admitted between 1994 and 2000 with respiratory
conditions during pregnancy, the hospitalization rate was 150/100,000, an admission rate
considerably higher than that of nonpregnant women (17/100,000) and corresponding to the
rate for people aged 65–69 [5]. Healthy pregnant women ages 20–34 were estimated to be 18
times more likely to be hospitalized for influenza than their nonpregnant peers [5].
While hospitalization rates are increased in all trimesters of pregnancy [4, 15, 16], they are the
highest during the third trimester [5, 14, 16–18]. Likewise, there is a strong association of
maternal morbidity with this trimester of pregnancy. In a 2003 study, Hartert et al. showed that
cardiovascular hospitalization during influenza season increased with each trimester, nearly
threefold higher by the third trimester compared to the first trimester [18]. In a study of 8323
healthy pregnant and postpartum women, Lindsay et al. found that the strength of association
between influenza exposure and influenza-like illness (ILI) increased as the stage of pregnancy
progressed, reporting an odds ratio (OR) of 1.12 (CI, 0.79–1.59) during the first trimester, 1.30
(CI, 0.97–1.73) during the second trimester, and 1.84 (CI, 1.31–2.59) for the third trimester [14].
Other studies have reported that by the third trimester, healthy pregnant women with no
comorbidity have the same risk for ILI-associated hospitalization as nonpregnant women with
chronic or comorbid conditions [4, 5].
Pregnant women with comorbid conditions such as asthma, diabetes, heart disease, or chronic
obstructive pulmonary disease are even more likely to be hospitalized than are pregnant
women without chronic conditions [5, 14, 16–18]. Neuzil et al. reported event rates for influenza
for low-risk women of 3, 6, and 10 per 10,000 women months in the first, second, and third
trimesters, respectively. The event rate in nonpregnant women was 2 per 10,000 women
months. Among women with chronic comorbid conditions, rates of 31, 16, and 21 per 10,000
women months were observed during these trimesters, respectively [4].
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While considerable data demonstrate increased morbidity and hospitalization from seasonal
influenza in pregnant women, mortality appears to be rare in healthy pregnant women during
non-pandemic seasons [7, 19, 20]. A study of seasonal influenza among pregnant women over
an 8-year period reported an average of five deaths per year and a mean mortality ratio of 2.9
per million live births [21]. However, during pandemics, influenza infection presents a
significant increased risk of both morbidity and mortality in pregnant women.
For example, during the pandemic of 1918, pneumonia was reported in 50% of previously
healthy pregnant women, leading to case-fatality rates of over 50% [22–26]. In the 1957
pandemic, 50% of the women of childbearing age who died of influenza were pregnant.
Furthermore, 10% of all influenza deaths during this pandemic occurred in pregnant women,
with the majority occurring during the third trimester [23, 24].
Increased rates of morbidity and mortality in pregnant women also were observed more
recently during the 2009 influenza A(H1N1)pdm09 pandemic. In fact, the first reported death
of an adult in the United States during this pandemic was a pregnant woman [27]. Of the 45
deaths reported early in the pandemic, 6 (13.3%) were pregnant women, all of whom developed
viral pneumonia and respiratory distress syndrome [27–29].
A study of pregnant US women with confirmed or probable influenza during the first month
of the outbreak reported 11/34 cases (32.4%) resulted in hospitalization—admissions rates four
times higher than those in the general population [30]. Deaths were reported in all three
trimesters and were independent of preexisting risk factors. In a California study, pregnant
women who were hospitalized with or died from pH1N1 were less likely than nonpregnant
women to have a predisposing or comorbid medical condition [31].
A review of published studies following the 2009 pandemic documented that pregnant women
were disproportionately represented among hospitalizations, ICU admissions, and deaths.
The 120 papers that were included in the review reported 3110 pregnant women from 29
countries with A(H1N1)pdm09 influenza infection, including 1625 (52.3%) who were hospi-
talized with 2009 H1N1, of whom 378 (23.3%) were admitted to an ICU and 130 (8%) died [32].
Pooling the data from all of the studies included in the review, the authors reported that
pregnant women, who represent approximately 1% of the population of United States and
Australia, accounted for 6.3% of hospitalizations, 5.9% of ICU admissions, and 5.7% of deaths
[32].
Using data from the Centers for Disease Control (CDC) and the Pregnancy Mortality Surveil-
lance System, Callaghan et al. estimated the total burden of pregnancy-related mortality
resulting from the 2009 to 2010 pandemic. Confirmed and possible deaths resulting from
A(H1N1)pdm09 infection represented the leading cause of pregnancy-related mortality in the
United States between the months of April 2009 and June 2010. Of 915 total pregnancy-related
deaths during this period, 12% of pregnancy-related deaths were attributed to influenza, 75
(8.2%) classified as confirmed influenza A(H1N1)pdm09 deaths, and 34 (3.7%) classified as
possible influenza infection deaths [33]. The authors calculated the pregnancy-related morality
ratio for confirmed and possible influenza deaths at 2.2 per 100,000 live births. This represents
a significant burden of mortality. The number of deaths (109) during the 2009–2010 influenza
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season was 20 times greater than the mean number (5) of annual possible influenza deaths
reported in a 1998–2005 cohort of pregnancy-related deaths in non-pandemic years [33].
Infants born to influenza-infected women during the pandemic also experienced increased
risks of poor clinical outcomes, mostly due to preterm birth. Reports of preterm birth rates
ranged from 15 to 30% among infected women [32, 34–36]. Infection with A(H1N1)pdm09 was
associated with increased risk of cesarean delivery [32]. In most cases, cesarean delivery was
an attempt to improve worsening maternal status rather than out of concern for the infant [32].
Siston et al. reported a cesarean delivery rate of 58% in pregnant women with 2009 H1N1
compared to a baseline cesarean rate of 30.5% [32, 34, 37]. While cesarean deliveries were
commonly described, it is likely that this rate was over-reported, since many of the studies
reported only severely affected women. Many deliveries were emergencies and performed
outside of controlled operating room settings, indicating the urgent nature of these deliveries
and the critical status of the women [32].
3. Influenza infection and fetal development
While there is no clear consensus on transplacental transmission of influenza virus or direct
viral effects on the fetus [2], the spread of virus beyond the respiratory tract during acute
infection is unusual, and vertical transmission, although documented [38–40], appears to be
rare [41, 42]. However, even in the absence of vertical transmission, adverse fetal effects can
occur, most likely due to the systemic maternal immune response to the infection [43, 44].
Studies have documented inflammatory responses in fetal tissues in response to influenza
infection. Such responses could impact the maternal-fetal interface, the placenta, or the fetus
directly, leading to pregnancy loss [43]. In addition to direct damage from inflammatory
responses, it is hypothesized that maternal hyperthermia can result in adverse fetal outcomes
[28, 45]. Maternal hyperthermia during the first trimester of pregnancy, regardless of the cause,
has been associated with an increased risk for neural tube defects [46], while fever during labor
has been associated with adverse outcomes including neonatal seizures, cerebral palsy,
encephalopathy, and death [2, 47–50].
In a large population-based study of influenza infection in over 100,000 women, Hansen et al.
observed an increased risk for fetal abnormalities (e.g., central nervous system malfunctions
in the fetus, chromosomal abnormalities, suspected damage to the fetus from viral disease)
was present in both seasonal (OR 1.53, CI, 1.19–1.95) and pandemic infections (OR 1.48, CI,
1.27–1.73) [51].
A review and meta-analysis of 33 studies published from 1953 to 2013 of first-trimester
influenza exposure found that influenza exposure during the first trimester of pregnancy was
associated with an increase in congenital abnormalities [adjusted odds ratio (AOR) 2.00, CI,
1.62–4.28]. Anomalies included neural tube defects [odds ratio (OR) 3.33, CI, 2.05–5.40],
hydrocephaly (OR 5.74, 1.10–30.00), congenital heart defects (OR 1.56, 1.13–2.14), cleft lip (OR
3.12, CI, 2.20–4.42), digestive system anomalies (OR 1.72, CI, 1.09–2.68), and limb reduction
defects (OR 2.03, CI, 1.27–3.27) [52]. A major limitation of this study concerns the fact that it
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defined influenza exposure as any reported influenza, influenza-like illness, or fever with or
without clinical confirmation. The inclusion of wide clinical symptoms without laboratory
confirmation of influenza likely resulted in overestimation of the number of infants exposed
to influenza during gestation. It therefore cannot be determined whether congenital abnor-
malities were associated with general, all cause hyperthermia or whether influenza infection
poses a unique and specific risk for these outcomes. Nonetheless, these observations suggest
that prevention of influenza during the first trimester of pregnancy may reduce risk for
congenital abnormalities.
Fetal demise is associated with influenza infection as well. Women with influenza, especially
those with pneumonia, had high rates of spontaneous abortion and preterm birth, with 52%
of pregnancies ending in spontaneous abortion or preterm delivery during the 1918 pandemic
[22, 23, 25].
Using a large nationwide registry, Haberg et al. examined the risk of fetal death after maternal
exposure to pandemic influenza infection. The researchers found that pregnant women with
a clinical diagnosis of influenza had a nearly twofold increase in the risk of fetal death (adjusted
hazard ratio, 1.91; 95% CI, 1.07–3.41) as compared to women who were not exposed to influenza
[53].
Pierce et al. assessed perinatal outcomes of maternal A(H1N1)pdm09 infection. The authors
found that perinatal mortality was higher in infants born to infected women than in infants of
uninfected women (39 per 1000 live births versus 7 per 1000 total births, respectively, p = 0.001).
This was principally explained by an increase in the rate of stillbirth (27 per 1000 total births
versus 6 per 1000 total births, p = 0.001) [54].
4. Influenza infection in neonates and young infants
Infants younger than 6 months of age are at a heightened risk for serious illness from influenza,
exhibiting the highest rates of severe influenza compared to other pediatric populations [41].
This age group has higher rates of hospitalization, more prolonged ICU stays, and higher
fatality rates (0.33 per 100,000 children) than almost any other age group [55–59]. In the United
States, estimates of hospitalization rates for young infants (less than 6 months of age) range
between 1.8 and 7.2 per 1000 infants, higher than reported rates of hospitalization for children
up to 4 years of age (0.14 per 1000) [60] and people 65–80 years of age (0.56–2.13 per 1000) [60–
63]. Childhood deaths associated with influenza are most frequent in infants during the first
months of life, with mortality rates in infants 0–6 months old more than four times higher than
those in older children [59].
Libster et al. [64] documented particularly high mortality rates for infants during the 2009
H1N1 pandemic in Argentina. Of 251 infants and children hospitalized with confirmed
A(H1N1)pdm09 infection, 13 (5%) died, for an overall death rate of 1.1 per 100,000 children.
Infants were at particularly high risk for fatality, representing the highest death rate at 7.6 per
100,000 children. By comparison, this death rate was 10 times the reported US infant death rate
during the relatively serious seasonal influenza season of 2003–2004 [59, 64].
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Taken together, these observations highlight the impact of influenza on infants, especially the
youngest, and underscore the need for prevention in this vulnerable population.
5. Maternal influenza vaccination
A large body of evidence collected over several decades demonstrates that pregnant women
and young infants are at increased risk for complications from influenza, making control of
influenza infection in these populations an important public health challenge. Influenza
vaccines have been used since 1945 and currently are the primary strategy for preventing
influenza infection [65].
Due to the frequent changes of the influenza viral antigens, a vaccine is formatted during the
end of the previous season to include the specific antigens of the influenza strains expected to
circulate in the following season, with a goal of conferring protection against the upcoming
season’s strains. Each year, the trivalent inactivated influenza vaccines (IIV3) are formulated
to contain three viral components: two influenza A subtypes and one influenza B virus. In 2012,
the US Food and Drug Administration (FDA) approved the use of a quadrivalent influenza
vaccine (IIV4). The quadrivalent vaccine contains two influenza A subtypes and two influenza
B subtypes. In 2009, a monovalent H1N1 vaccine was prepared because the newly recognized
strain was identified too late in the season to be included in the trivalent seasonal vaccines [66].
The current inactivated influenza vaccines (IIVs) are composed of inactivated (killed) virus
that has been chemically disrupted and purified to form a split-inactivated virus preparation.
Such split-virus vaccines contain purified HA and NA antigens and have fewer side effects
and reactions than inactivated whole virus vaccines. The IIVs currently available in the United
States are split virus or subunit virus similar to the split virus [66].
The other vaccine available in the United States is a live, attenuated influenza vaccine (LAIV).
This vaccine is composed of live, attenuated, cold-adapted, temperature-sensitive virus
administered directly into the nasal passage. The type A and B strains of influenza in this
vaccine can replicate in the nasal passages, stimulating an immune response, but cannot
replicate in the lower respiratory tract [67]. While LAIV has been licensed in the United States
since 2003, it is not recommended for use in pregnant women [68].
A strategy to increase the effectiveness of IIVs is the addition of adjuvants. Adjuvants are
compounds that stimulate the immune system to mount a more robust and protective response
to the vaccine. The most commonly used adjuvants in influenza vaccines are the oil-based
compounds AS03 and MF59. Adjuvants can allow for the use of lower doses of antigen,
resulting in more available doses of vaccine, which may be useful in times of high demand
such as during pandemics. While adjuvanted vaccines are not approved for use in pregnant
women in the United States, in Canada, and in many European countries, the pandemic vaccine
was formulated with adjuvant and administered to pregnant women [69].
Vaccination of pregnant women with IIV has taken place since the 1960s. Universal recom-
mendation for vaccinating woman at all stages of pregnancy has been recommended by the
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CDC’s Advisory Committee on Immunization Practices (ACIP) since 2004 [65, 70, 71] and by
the World Health Organization (WHO) since 2005 [1]. The Advisory Committee on Immuni-
zation Practices does not preferentially recommend a specific formulation—trivalent or
quadrivalent—of the influenza vaccine [72]. In response to the 2009 H1N1 pandemic, the WHO
placed pregnant women, along with caregivers of infants younger than 6 months old, health-
care and emergency services personnel, individuals between 6 months and 24 years, and those
aged 25 years or older with chronic medical conditions, in the highest priority group to receive
vaccines [73].
The American College of Obstetrics and Gynecology (ACOG) considers prevention of
influenza to be an “essential element of prenatal care” [74]. In full support of the ACIP
recommendations, ACOG issued new guidelines in September of 2010 stating that all unvac-
cinated pregnant women at any gestational age be vaccinated against influenza [74].
It is well documented that the antibody (Ab) response to influenza vaccine in pregnant women
is similar to that of age-matched, nonpregnant women [75–79]. These observations support a
conclusion that influenza vaccination will lead to an effective immune response in pregnant
women and thereby provide an important tool in prevention of influenza in this population.
5.1. Effectiveness of maternal influenza vaccines
Pregnant women and neonates are high-risk groups for complications from influenza infec-
tion. Control of influenza in this population is an important public health concern. However,
due in part to ethical concerns related to enrolling pregnant women in clinical studies,
experimental data on influenza vaccination during pregnancy has been scarce, and the quality
of the evidence is not consistently high overall [80].
Prior to 2010, there were few well-designed studies specifically addressing vaccine effective-
ness in pregnant women. From 1964 to 2008, four studies specifically addressed vaccine
effectiveness in pregnant women (Table 1). These studies covered eight different influenza
seasons and included 51,547 pregnant women.
During a 1962–1963 outbreak of Asian influenza, Hulka measured vaccine effectiveness in
pregnant women by asking immunized and nonimmunized patients if they had experienced
influenza symptoms during the influenza season. While fewer immunized than unimmunized
patients reported respiratory illness with fever (11% versus 20%, respectively), there was no
significant difference in reports of respiratory illness between these patients [76].
Black et al. assessed vaccine effectiveness in almost 50,000 pregnant women across five
influenza seasons. Vaccine effectiveness was determined by the number of outpatient visits for
ILI or hospitalization for influenza or pneumonia. Using these outcomes, the risk of medical
visit for respiratory symptoms was no different between vaccinated and unvaccinated women,
and hospitalization was rare in both groups [81]. Using the adjusted hazard ratios
(AHR = 1.151; CI, 0.979–1.352) from this study, Skowronski and De Serres calculated a vaccine
effectiveness of −15% (CI, −35 to 2%) for this study population [7].
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In a retrospective case-control study of five influenza seasons (1995–2003), Munoz et al.
estimated the potential protective effect of vaccination by recording the occurrence of acute
respiratory infection (ARI) in vaccinated and unvaccinated women. The researchers reported
a nonsignificant (p = 0.24) trend toward lower incidence of medically attended ARI in vacci-
nated women as compared to unvaccinated women (22.6% of the vaccinated cohort versus
18.9% of the unvaccinated cohort) [82]. Among the women who developed ARI, the number
of episodes of ARI was the same, 1.4 illnesses/person in both groups. However, there was a
difference in the timing of these episodes, with 9% of the vaccinated cohort reporting ARI
episodes during the peak of the influenza season, while 19% of the ARI events in the unvac-
cinated cohort occurred during the peak (p = 0.01, CI, 0.1–0.8) [82]. In this study, only three
women were diagnosed with ILI, one vaccinated and two unvaccinated women, all during the
peak influenza seasons of 1999–2000 and 2000–2001. These low rates of ILI as well as the small
number of vaccinated women in the study population (vaccination rate was 3.5%) are limita-
tions of this study. Using the relative risks reported in the study, vaccine effectiveness was
−20% for ARI any time during pregnancy (CI, −59 to 9%) and 39% (CI, −56 to 76%) during the
peak of the influenza season [7].
Study  Study
period 
Participants  Outcomes
measured 
Influenza vaccine protection 
Studies of seasonal IIV during pregnancy 
Hulka [76]  1962–1963  544 pregnant women
-363 immunized
-181 nonimmunized
176 nonpregnant women
-138 immunized
-38 nonimmunized 
Incidence of
influenza-like
illness (ILI) 
Nonsignificant reduction in
incidence of ILI (20% versus 11%) 
Black et al.
[81] 
1997–2002  49,585 pregnant women
-3707 immunized
-45,878 nonimmunized 
Medical visit for
respiratory
symptoms 
No difference in medical visits
(p = 0.088)
Adjusted hazard ratio = 1.151;
(CI, 0.979–1.352)
Clinical effectiveness: −15%
Excluding medical visits for asthma,
no difference (p = 0.988)
Adjusted hazard ratio = 1.001
(CI, 0.838–1.196)
Clinical effectiveness: 0% 
Munoz et al.
[117] 
1998–2003  Pregnant women
-252 immunized
-826 nonimmunized 
Medically
attended acute
respiratory illness
(ARI) 
Nonsignificant trend toward lower
incidence of ARI (22.6% versus 18.9%;
p = 0.24)
Clinical effectiveness: −20%
(CI, −59.5 to 9%) any time during
pregnancy
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Study  Study
period 
Participants  Outcomes
measured 
Influenza vaccine protection 
39% (CI, −56 to 76%) during peak of
influenza season 
Zaman et al.
[79]  
2004–2005  340 pregnant women
-172 immunized with TIV
-168 immunized with
pneumococcal vaccine 
Respiratory
illness with fever 
Significant reduction of respiratory
illness with any fever:
Risk difference: −14.2
(CI, −25.5 to 2.9)
Clinical effectiveness: 35.8%
(CI, 3.7–57.2%)
Reduction in respiratory
disease with fever over 38 °C:
Risk difference: −7.3%
(CI, −14.5 to 0.1%)
Clinical effectiveness: 43.1%
(CI, −9.0 to 70.3%) 
Madhi et al.
[83]  
2011–2012  2116 pregnant women
-1062 immunized with IIV3
-1054 received placebo 
RT-PCR-
confirmed
influenza 
Clinical effectiveness: 50.4%
(CI, 14.5–71.2%) 
Thompson
et al. [84]  
2010–2012  Pregnant women
-100 with confirmed
influenza
-192 with ARI negative for
influenza
-200 control negative for
influenza 
RT-PCR-
confirmed
influenza 
Clinical effectiveness: 44%
(CI, 5–67%) compared to influenza-
negative controls 53%
(CI, 24–72%) compared to
ARI-negative controls 
Studies of PH1N1 vaccine during pregnancy 
Richards et al.
[101] 
2009–2010  1125 vaccinated
1581 non-vaccinated
(unadjuvanted vaccine) 
RT-PCR or
medical visit during
pregnancy with
influenza-related
ICD-9 diagnosis
code 
Clinical effectiveness: 61.5%
(CI, 15.5–82.5%) 
Haberg et al.
[53]  
2009–2010  117,347 pregnant women
(adjuvanted vaccine) 
Clinical effectiveness: 70% (AHR, 0.30;
(CI), 0.25–0.34) 
Table 1. Clinical effectiveness of IIV and A(H1N1)pdm09 influenza vaccine during pregnancy.
The authors of this study speculate that while the receipt of an influenza vaccine may not
prevent infection, it is likely to reduce the severity of the disease. However, they provided no
data on clinical severity or evidence of such an association with vaccination status. Since there
was no confirmation of influenza infection in most patients with ARI, it is impossible to confirm
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whether clinical symptoms were associated with influenza infection or with other respirato-
ry viruses.
In 2008, Zaman et al. published the first randomized, double-blind, controlled clinical trial
(RCT) of influenza vaccine in pregnant women. In this study, 340 pregnant women were
randomized to receive either trivalent influenza vaccine (IIV3) or pneumococcal polysacchar-
ide vaccine during the third trimester of pregnancy. This study was part of The Mother’s Gift
project, a randomized trial with the primary goal of assessing the safety and immunogenicity
of pneumococcal vaccines. Therefore, the control arm consisted of mothers who received the
pneumococcal vaccine, providing a control for an active, non-influenza vaccine. The authors
measured nonspecific respiratory illness with fever and found that vaccinated women were
significantly less likely to have respiratory illness, reporting a clinical effectiveness of 35.8%
(CI, 3.7–57.2%) for respiratory illness with any fever and 43.1% for fever over 38 °C (CI, −9.0
to 70.3%) [79].
All of these studies share the common weakness that they use clinical symptoms, and not
laboratory-confirmed influenza, as the primary outcome. Influenza vaccines are specifically
targeted to influenza viruses. Many other respiratory pathogens can cause symptoms similar
to influenza, but influenza vaccines are not designed to prevent other causes of influenza-like
illness. Hence, clinical symptoms without laboratory confirmation are nonspecific outcomes.
Interpretation and quantification of true vaccine effectiveness using only clinical outcomes are
problematic, potentially leading to inaccurate estimates of effectiveness. For this reason,
laboratory confirmation, either by reverse transcription polymerase chain reaction (RT-PCR)
or viral culture, remains the best diagnostic tool for confirming influenza and evaluating
vaccine efficacy (VE) and effectiveness.
In 2014, two studies began to address this deficiency in the literature. The research teams
estimated influenza vaccine effectiveness in preventing illness among pregnant women using
laboratory-confirmed (RT-PCR) influenza as the primary outcome.
Madhi et al. examined maternal and fetal outcomes in 2116 HIV-negative South African women
during the 2011–2012 influenza season. 1062 women who received IIV3 were compared to
women who received a placebo. Overall vaccine effectiveness at preventing laboratory-
confirmed (RT-PCR) influenza in this population was 50.4% (CI, 14.5–71.2) [83].
Using a large health plan database, the Pregnancy and Influenza Project evaluated seasonal
vaccine efficacy during the 2010–2011 and 2011–2012 influenza seasons. The authors compared
the proportion of vaccinated women among 100 RT-PCR-confirmed influenza cases with the
proportion vaccinated among 192 women with ARI who tested negative for influenza, and 200
controls matched by season, site, and trimester [84]. The adjusted vaccine efficacy against
influenza was of 44% (CI, 5–67%) using the influenza-negative controls and 53% (CI, 24–72%)
for the ARI-negative controls [84].
The 2009 A(H1N1) pandemic provided an opportunity to improve understanding of influenza
vaccination during pregnancy. The pandemic allowed an evaluation of the effectiveness of
maternal vaccination during an influenza season in which there was a high rate of viral
circulation, as well as a close match between the vaccine strain and the circulating viral strain.
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Pregnant women were prioritized to receive the vaccine and were strongly advised to be
vaccinated [85], resulting in higher than usual vaccination rates [86].
Since the 2009 pandemic, a number of studies have examined monovalent pandemic A(H1N1)
vaccination of pregnant women. Synthesizing evidence from this new and expanding database
should increase our understanding of maternal influenza vaccination. While most of these
studies measured either seroconversion and hemagglutinin inhibition (HAI) titers [87–92] or
safety and/or birth outcomes [93–100], two studies specifically examined clinical efficacy of
pandemic A(H1N1) vaccine during pregnancy.
In a retrospective cohort study, Richards et al. evaluated influenza infection in 1125 vaccinated
and 1581 non-vaccinated women. In this study, influenza infection was defined as testing
positive for influenza by RT-PCR or having a medical visit during pregnancy with influenza-
related ICD-9 diagnosis code during the period of 2009 influenza A(H1N1) virus circulation
[101]. The researchers reported a vaccine efficacy (VE) of 61.5% (CI, 15.5–82.5%) for 2009 H1N1
influenza vaccine against diagnosed 2009 influenza A(H1N1) infection during the study period
among all mothers in the study cohort [101].
A separate population-based study of 117,347 pregnant women in Norway estimated that
vaccination during the second or third trimester of pregnancy resulted in a 70% reduction in
influenza diagnosis following vaccination with adjuvanted A(H1N1) vaccine (adjusted hazard
ratio, 0.30; CI, 0.25–0.34) [53].
While there is significant heterogeneity among these eight clinical studies, presenting wide-
ranging estimates of vaccine effectiveness in pregnant women (from −15 to 70%), the evidence
of effectiveness data based on laboratory-confirmed influenza is mounting and compelling.
The cumulative evidence to date provides three studies showing significant clinical effective-
ness during seasonal influenza years, 35.8% against respiratory disease in a RCT [79], 50.4%
protection against laboratory-confirmed influenza in a RCT [83], and one large data-base study
documenting VE of 44–53% [84]. Two studies of vaccine effectiveness during the 2009 A(H1N1)
pandemic estimated VE of 61.5% (unadjuvanted) and 70% (adjuvanted), suggesting that
vaccination during a pandemic season may offer more benefit than during non-pandemic
years.
These more recent estimates using laboratory-confirmed endpoints are well within the
reported vaccine effectiveness for healthy, nonpregnant adults. When combined with the well-
documented observation that the antibody response to influenza vaccine in pregnant women
is similar to that of nonpregnant women, all current evidence suggests that efficacy of influenza
vaccines in pregnant women is similar to the nonpregnant population.
5.2. Maternal vaccination to protect young infants
An important secondary benefit of maternal vaccination appears to be protection of infants
from influenza infection during the first months of life, providing an important two-for-one
benefit since no influenza vaccine is licensed or recommended for infants younger than 6
months of age.
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Maternal vaccination has potential to protect newborns due to the transfer of maternal
immunity. Transplacental transfer of antibodies occurs throughout pregnancy, with highest
levels during the last 4–6 weeks of gestation [102, 103]. Antibodies (specifically IgG) cross the
placenta from mother to fetus during the final weeks of pregnancy, while infants acquire
additional immune protection during breastfeeding, when the main class of immunoglobulin
transferred in breast milk is IgA [104].
Several studies have demonstrated transplacentally acquired antibodies after natural influenza
infection in the mother. One study examined the cord sera of 26 infants who had culture-
confirmed influenza when younger than 4 months of age. The authors found a direct correla-
tion between the gestational age at the time of infection and the level of antibody in the cord
serum (p = 0.002), suggesting a protective effect of transplacentally acquired antibody [105].
During the 1979 influenza epidemic, infants of mothers with serum antibody to influenza
(seropositive) were compared to infants of mothers who were seronegative [106]. The infants
of seropositive mothers had higher specific serum antibody (IgG) titers against the HA
influenza protein than did infants of seronegative mothers. Good correlation was found
between maternal antibody titers and titers in infants (correlation, 0.81). No such correlation
was found for non-immune mothers and their infants (correlation, 0.24) [106]. However, this
study showed no difference in incidence of influenza infection, although infants of immune
mothers showed delayed onset of symptoms and shorter duration of illness, suggesting that
passive maternal immunization may delay onset and severity.
5.2.1. Serological studies
When evaluating vaccination response to influenza, a serum antibody titer of ≥1:40 against the
HA protein is considered to be clinically relevant, resulting in a 50% decrease in symptomatic
infection and, therefore, serving as a correlate of protective immunity [107]. Recent analysis of
published data indicates an even higher level of clinical protection, estimating that 70% of
participants are protected at a titer of 1:40, with protection increasing gradually with higher
titers [108].
In the absence of a widely accepted immune correlate of protection for influenza, the analysis
of hemagglutinin inhibition (HAI) seroprotection rates is generally considered a useful
indicator of protection in vaccinated persons. There are challenges associated with using this
antibody titer as a correlate of protection in infants, however, particularly since this correlate
was determined in healthy adults [41, 107]. In any event, the US Food and Drug Administration
(FDA) uses this HAI antibody titer in evaluation of influenza vaccines, making the HAI
antibody titer the standard used by most investigators [40], including those examining vaccine
protection in neonates.
In a study examining transplacental transfer of antibody in response to vaccination, Englund
et al. studied women during the last trimester of pregnancy who were vaccinated with IIV3
(A/Sichuan/H3N2, A/Taiwan/H1N1, B/Victoria). Maternal immunization resulted in the
transfer of influenza-specific IgG to the infants. When measured at the time of delivery, the
levels of antibody transferred were high, with between 87 and 99% of antibody detectable in
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the mother also detectable in the infant [78]. The antibody titers to at least two of the three
influenza antigens (influenza H3N2 and influenza B) remained significantly elevated up to 2
months of age [78].
Sumaya and Gibbs vaccinated pregnant women and reported a similar correlation, finding
that cord blood HAI antibody in infants correlated with titers of vaccine-stimulated HAI
antibody in mothers, with HAI antibody detected in 54% of newborn serum and 73% of
maternal serum [75]. This study did not examine infant influenza infection as an outcome, so
the study was unable to correlate serum antibody levels with clinical outcome.
While these previous studies demonstrated that maternal antibody appears to be transferred
to infants following both natural infection and vaccination, neither study discussed whether
the level maternal antibody was high enough to confer protective immunity to the infant [41,
107]. Using HAI titer as a correlate of immunity, Steinhoff et al. did conduct an RCT of maternal
influenza vaccine. Serum samples were obtained from 311 mothers before vaccination and at
delivery and from 292 infants at birth at 10 weeks and 20–26 weeks later [109]. The proportion
of mothers with a protective antibody titer (HAI ≥ 1:40) at the time of delivery was 88% for A/
New Caledonia (H1N1), 98% for A/Fujian (H3N2), and 45% for B/Hong Kong. Similar
proportions of infants had protective antibody titers at birth [109].
Yamaguchi et al. also examined the immune responses to influenza vaccination during
pregnancy by measuring the effect of influenza vaccination (IIV3) in pregnancy, including
maintenance of the specific antibody response, and the efficiency of transplacental transfer of
the antibody to the fetus. The study included 125 pregnant women, 71 in their second trimester
and 54 during the third trimester of pregnancy. The authors reported that vaccination at any
time during pregnancy yielded protective levels of antibody in both maternal and fetal blood
[110].
In a prospective study examining the immunogenicity and transplacental transmission of
antibodies in pregnant women in Asia, Lin et al. enrolled 46 pregnant women who received a
single dose of IIV3. Twenty-eight days after vaccination, the seroprotection rate in vaccinated
women against H1N1, H3N2, and influenza B was 91.3, 84.8, and 56.5%, respectively [111].
Several additional studies have demonstrated transplacental antibody transfer following
maternal vaccination with pandemic H1N1 vaccine. Three studies evaluated adjuvanted
A(H1N1) vaccines, and two studied nonadjuvanted A(H1N1)vaccine. All five of the studies
documented protective levels of antibody in significant percent of infants (79–95%).
Zuccotti et al. followed 69 mother-infant pairs. The women were vaccinated during their third
trimester of pregnancy with MF59-adjuvanted influenza A(H1N1) vaccine. All of the mothers
had HAI antibody titers at or above 1:40 at the time of delivery and throughout the 5 months
of follow-up. Ninety-five percent of the infants had HAI antibody titers at or about 1:40 at both
birth and 2 months of age. By 5 months of age, the proportion of infants with titers of 1:40
dropped to 81.2% [89], suggesting that passively acquired antibody at levels thought to be
protective is transferred and persists for at least 5 months.
In a separate study performed at three sites in the UK, researchers followed infants born to
mothers who were vaccinated with AS03-adjuvanted H1N1 vaccine during the second or third
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trimester of pregnancy. This study found that 79% of the infants of vaccinated mothers had
serum antibody titers at or higher than 1:40 compared to a background immunity in 19% of
infants of unvaccinated women (p = 0.001) [112].
Helmig et al. evaluated the serological response of a cohort of women immunized with
adjuvanted A(H1N1) vaccine or by natural infection with A(H1N1)pdm09. The authors
detected protective antibody levels (>1:40) in a significant number 17/19 (89.5%) of newborns
born to vaccinated mothers (p = 0.001) [113]. Notably, while natural influenza infection
conferred protective antibody levels in mothers, it did not contribute to protective levels in
their infants; only 15.8% of infants born to women who had natural influenza infection during
pregnancy developed protective levels of antibody at birth.
In a study of nonadjuvanted A(H1N1) vaccine, Tsatsaris et al. measured Ab titers in cord blood
of 88 infants born to women vaccinated with a single dose of monovalent A(H1N1) vaccine.
The researchers reported 95% (CI, 89–99%) of infants have protective levels of antibody (>1:40)
at birth [114], and Fisher et al. also reported protective levels of Ab in cord blood of infants
following maternal vaccination with 2009 monovalent A(H1N1) [115].
Taken together, these studies provide an important proof of concept for transplacentally
acquired antibody, from either natural infection or vaccination of their mother, to potentially
protect young infants from influenza infection and present maternal immunization as a
promising strategy for reducing influenza infection in infants.
5.2.2. Clinical studies
Over the past 11 years, nine studies have been published evaluating the effect of maternal
immunization on influenza in 97,656 infants across 15 influenza seasons. Six of these studies
showed clinical protection; three studies did not (Table 2).
Study  Study
period 
Participants  Outcomes measured  Protection by maternal influenza
vaccine 
Black et al.
[81] 
1997–
2002 
49,585 pregnant women Hospitalization for
pneumonia and
influenza 
No difference in risk for hospitalization
(p = 0.235)
Adjusted hazard ratio: 0.956 (CI, 0.889–
1.029)
Clinical effectiveness: 4% (CI, –3 to 11%)
No difference in risk including otitis
media visit (p = 0.506)
Adjusted hazard ratio: 0.938 (CI, 0.777–
1.132)
Clinical effectiveness: 6% (CI, –13 to
22%) 
Munoz et al.
[117] 
1998–
2003 
225 infants of
immunized mothers
Hospitalization or No difference in hospitalization
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Study  Study
period 
Participants  Outcomes measured  Protection by maternal influenza
vaccine 
826 infants of
nonimmunized
mothers 
clinic visits for
respiratory conditions 
During first month, infants of immunized
moms had more clinic visits for
bronchitis (p = 0.04) and fewer for
respiratory distress (p = 0.04)
No other differences 
France et al.
[116] 
1995–
2001 
3160 infants of
immunized mothers
37,969 infants of
nonimmunized women 
Medically attended
acute respiratory illness
(ARI) 
No reduction in clinic visit rates
Incident rate ratio: 0.96 (CI, 0.86–1.07) 
Zaman et al.
[79] 
2004–
2005 
316 infant-mother pairs
followed for 24 weeks 
Clinic visits for
respiratory illness
Laboratory-confirmed
influenza before 24
weeks of age
(confirmation by rapid
test) 
63% effective at preventing laboratory-
confirmed influenza in infants up to 6
months old (CI, 5–85%)
29% effective in preventing febrile illness
(CI, 6.9–45.7%)
42% effective in preventing clinic visit
(CI, 18.2–58.8%) 
Benowitz et
al. [118] 
2000–
2009 
Infants less than 12
months old
-220 cases
-430 matched controls 
Laboratory-confirmed
influenza (confirmation
by direct fluorescent
antibody (DFA) test) 
91.5% effective at preventing
hospitalization of infants less than 6
months of age (p = 0.001; CI, 61.7–98.1%)
No significant effect on infants older than
6 months 
Eick et al.
[120] 
2002–
2005 
1169 infant-mother
pairs 
Laboratory-confirmed
influenza (confirmation
by viral culture,
fourfold rise in HAI
antibody in cord serum
or rapid test) 
Laboratory-confirmed influenza
decreased among infants born to
vaccinated women compared to controls
Risk ratio 0.59 (CI, 0.37–0.93)
Clinical effectiveness: 41%
Hospitalization
Risk ratio 0.61 (CI, 0.45–0.84)
Clinical effectiveness: 39% 
Poehling et
al. [126] 
2002–
2009 
Infants less than
6 months old
hospitalized with
fever or
respiratory symptoms
-151 cases
-1359 controls 
Laboratory-confirmed
influenza (confirmation
by viral culture or
PCR) 
Hospitalized infants whose mothers were
immunized were 45–48% less likely to
have laboratory-confirmed influenza
Adjusted odds ratio (OR) 0.52
(CI, 0.30–0.91) 
Sugimura et
al. [127] 
2010–
2011 
200 infants from birth
to 6 months of age
-106 infants of
vaccinated mothers
Laboratory-confirmed
influenza (confirmation
by rapid test) 
Significant difference in incidence of
influenza between infants of vaccinated
versus unvaccinated mothers
(p = 0.019) 
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Study  Study
period 
Participants  Outcomes measured  Protection by maternal influenza
vaccine 
-90 infants of
unvaccinated mothers 
Madhi et al.
[83] 
2011–
2012 
2046 infants
-1026 infants of
vaccinated mothers
- 1023 infants of
placebo mothers 
Laboratory-confirmed
influenza RT-PCR 
Vaccine efficacy of 48.8% (CI, 11.6–
70.4%) 
Table 2. Clinical effectiveness of maternal vaccination for protection of infants.
5.2.2.1. Studies finding no protective effect
In a retrospective cohort study of 48,639 infants, Black et al. found that infants born to
vaccinated women had the same risk of hospitalization for influenza or pneumonia as infants
of unvaccinated women (CI, 0.889–1.029). They also reported that maternal vaccination was
not a significant determinant of risk for ILI or otitis media [81].
France et al. followed 3160 infants of immunized mothers and 37,969 infants of nonimmunized
mothers from 1995–2001 and during four specific seasonal periods: peak influenza, respiratory
syncytial virus predominant, periseasonal, and summer weeks [116]. They found no difference
in medically attended ARI (incident rate ratio for peak influenza season 0.96, CI, 0.86–1.07),
concluding “maternal influenza vaccination did not reduce visit rates during any of the four
time periods and did not delay the onset of first respiratory illness” [116].
In a study that included an examination of data over five influenza seasons, Munoz et al.
reported similar results, finding no difference in hospitalizations for respiratory illness during
the peak of influenza season between infants of vaccinated mothers versus infants of non-
vaccinated mothers [117].
5.2.2.2. Studies finding clinical protection
While the three earlier studies above found no benefit to infants from maternal vaccination, a
more recent matched case-control study of infants less than 12 months old admitted to hospitals
for seasonal influenza between 2000 and 2009 reported maternal vaccination to be 91.5%
effective (CI, 61.7–98.1%, p = 0.001) in preventing hospitalization of infants younger than 6
months of age [118]. Maternal vaccination was not effective in preventing hospitalization for
infants older than 6 months (−41.4% (CI, 0.153–0.918)). In this study, influenza cases from 2007
to 2009 were confirmed by direct fluorescent antibody (DFA) test, which was reported to be
96.2% sensitive and 99% specific for influenza [119]. A limitation to this study is that results
from nine influenza seasons were combined, with no information regarding the strain match
of vaccine to circulating strain for each influenza season. The researchers did not type the strain
of influenza in infected infants, stating that they “did not have adequate power to assess the
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vaccine’s effectiveness by influenza season…and did not type strains to determine whether
influenza infections were caused by strains included in the vaccine” [118].
Eick et al. conducted a study in the White Mountain and Navajo reservations over three
influenza seasons, November 2002 to September of 2005. In this prospective cohort study, the
effect of influenza vaccine during pregnancy on influenza infection in infants was compared
between infants of vaccinated women and those born to non-vaccinated women. The authors
analyzed 83 confirmed influenza cases. Of these cases, seven (86%) were confirmed by serology,
ten (12%) by viral culture, and two (2%) by rapid influenza testing. Using these three measures
of influenza infection, the authors reported a 41% reduction in the risk of laboratory-confirmed
influenza for infants born to vaccinated women (RR 0.59, CI, 0.37–0.93) and a 39% reduction
in the risk of ILI hospitalization (RR 0.61, CI, 0.45–0.84) [120].
The authors of this study pooled the results from three different assay methods, each with
different sensitivities, to document influenza infection. Pooling assays with differing diagnos-
tics represents a limitation of this study. Likewise, the use of serology to document influenza
in most (86%) of cases represents a weakness of this study. The authors describe serological
documentation of influenza infection as a fourfold or greater increase in HAI antibody in serum
collected at 2–3 or 6 months compared with previous serum specimen [120]. Significant
limitations have been reported regarding the use of serology in diagnosing influenza in adult
patients that have been vaccinated with inactivated vaccines [121–123]. Using serology to
document influenza infection in young infants presents additional complications.
Infants under 6 months of age have immature, immunologically inexperienced immune
systems. Since their ability to produce antibody in response to infection is often delayed or
completely absent, many of their serum antibodies are maternally derived. More than 50 years
ago, the use of serology for diagnosis of influenza in infancy was questioned. During an
influenza outbreak in Glasgow in 1953, fourfold increases in antibody were found in only 20%
of infants admitted to pediatric pneumonia wards (as compared to 30% of adult cases) [124].
In two different outbreaks, antibody production was absent or considerably delayed in infected
children under 18 months of age, even when virus could be isolated [125]. These observations
illustrate the difficulties inherent in using serology to document influenza infection in young
infants.
In the only randomized, blinded clinical study to assess infant protection, Zaman et al. reported
a vaccine effectiveness of 63% (CI, 5–85%) against laboratory-confirmed influenza in infants
up to 6 months of age [79]. Influenza was confirmed by rapid test (Z Stat Flu), which was
reported to have a specificity of 80–90% and a sensitivity of 70–72% for type A and type B
influenza. When respiratory illness and fever were used as measure of disease, the reported
effectiveness was 29% (CI, 7–46%) [79].
A recent study sought to determine whether maternal vaccination during pregnancy was
associated with a reduced risk or laboratory-confirmed influenza hospitalizations in 1510
infants over seven consecutive influenza seasons (2002–2003 through 2008–2009) and across
three diverse geographic regions of the United States [126]. Of the 1510 infants hospitalized
with fever or respiratory symptoms, 151 (10%) had laboratory-confirmed (by viral culture or
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RT-PCR) influenza. The proportion of infants who were influenza positive varied significantly
across influenza seasons, from 3% in 2006–2007 to 15% in 2003–2004. The percentage of women
who were vaccinated also varied by season, from 10% in 2003–2004 to 38% in 2008–2009.
Among influenza-positive infants during all study years, 12% of their mothers reported being
vaccinated during pregnancy, while 20% of mothers of influenza-negative infants reported
receiving a vaccination [126], yielding an adjusted odds ratio of 0.52 (CI, 0.30–0.91) and
suggesting that infants whose mothers received influenza vaccines during pregnancy were
48% less likely to have laboratory-confirmed influenza than infants of unvaccinated women
[126].
In a randomized, placebo-controlled trial of influenza vaccination in South Africa, Madhi et
al. followed 1026 infants born to women who received IIV3 and 1023 infants born to placebo
recipients. The attack rate of influenza was lower among infants of vaccinated mothers (1.9%)
than among those whose mothers received placebo vaccine (3.6%), yielding a vaccine effec-
tiveness of 57.5% (CI, 7.6–70.4) in this population [83].
In a prospective study, Sugimura et al. assessed the incidence of fever and laboratory-con-
firmed influenza in newborns whose mothers were vaccinated during pregnancy with IIV3.
Two hundred infants were followed from birth to 6 months of age. Fever was noted in 36 (34%)
of the infants in the vaccinated group and 47 (52.2%) of infants born to unvaccinated mothers
(p < 0.007). The incidence of influenza as diagnosed by rapid test was 0 (0%) and 5 (5.6%),
respectively, (p = 0.019) [127].
The reviewed studies assessed hospitalization, clinic visits, ARI, or laboratory-confirmed
influenza as primary outcomes. Rationale for influenza vaccination often includes additional
secondary outcomes such as reduction of absenteeism for household contacts, secondary
infections, acute otitis media, or community transmission of influenza. While these outcomes
are important in measuring the broad impact of influenza, they do not provide accurate
assessment of vaccine efficacy or effectiveness. Such an assessment is essential for evidence-
based, reasoned development of public health policy and decision-making about influenza
prevention.
In summary, the evidence for newborn protection through maternal vaccination is encourag-
ing, but several studies exhibit methodological limitations. The results of studies measuring
rates of ARI, clinic visit, or hospitalization range from no vaccine effect up to 42% effectiveness
[81, 116, 117]. The six studies that used some form of laboratory-confirmed influenza (rapid
tests, viral culture, or PCR) as the primary outcome are more encouraging, reporting vaccina-
tion effectiveness ranging from 41 to 91.5% [79, 83, 118, 120, 126, 127].
While outcomes and study designs differ, in general the data to date suggest that maternal
vaccination has the potential to decrease influenza illness in newborns. As such, maternal
immunization during pregnancy should continue to be recommended and encouraged for all
women.
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6. Current challenges
Influenza is a complex disease. For centuries it has eluded complete understanding or control.
Constantly evolving and catching us by surprise, influenza is a perpetually emerging disease.
The main tool for prevention of influenza is vaccination, the cornerstone for prevention of
influenza disease. However, unlike many other vaccines, the effectiveness of influenza vaccines
remains moderate to marginal across all populations [128], and in addition, the vaccines need
to be administered every year. A universal influenza vaccine providing broad and long-lasting
protection continues to be elusive.
These realities—difficult enough in the general population—are even more challenging to
understand during pregnancy. Particularly complex is determining how, or if, the changing
immune responses over pregnancy vis-a-vis influenza season and vaccination schedules
impact vaccine effectiveness and disease outcomes in pregnant women.
A recent critique by Savitz et al. calls into question our most basic understanding of influenza
infection during pregnancy, with a particular critique on the quality of the evidence for a benefit
of maternal vaccination in prevention of harm from seasonal influenza [129]. Savitz et al.
discuss the complications inherent in many current research practices, which serve to limit our
understanding of the true picture of maternal influenza. Central to this critique is the notion
that both pregnancy and influenza have temporal components; influenza typically is seasonal,
with a 2–3-month period of circulation each year. But pregnancy has trimesters, each with
distinct fetal developmental stages along with physiological and immunological changes in
the expectant mother. To complicate this further, the risk of adverse outcomes from influenza
infection is not equal across all trimesters of pregnancy. Therefore, optimizing risk and benefit
of vaccination during pregnancy is complicated and likely requires reexamination of influenza
risk and benefit across trimesters in association with months of influenza circulation [129].
A recent WHO review of influenza throughout pregnancy found insufficient data from
comparable studies to discern which specific weeks, months, or trimesters influenza poses
increased risk to pregnant women [130]. Savitz et al. assert that “As with all time dependent
states, pregnancies must be followed longitudinally. There needs to be a week-by-week
consideration of the pregnancy with regard to vaccination status and circulating influenza
viruses” [129].
Aside from complications associated with potential differences in virus exposure across the
trimesters of a pregnancy, risks posed to pregnant women also may differ according to the
specific strain circulating during a given season, and, likewise, the immune response to
vaccination also could differ based on strain [131].
Even when taking yearly strain differences into account, variation in immune responses across
trimesters adds yet another complicating variable. It is widely accepted that the immune
response to influenza vaccine in pregnant women is indistinguishable from that of nonpreg-
nant women and that gestational age appears to have no effect on antibody response [75, 76,
132, 133].
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Findings from more recent studies suggest that we may need to entertain a more nuanced
approach to our understanding of the maternal immune response to influenza vaccination—
precisely because immunogenicity and seroconversion may not tell the entire story.
In a 2011 study, Ohfuji et al. reported a lower seroprotective antibody response to pandem-
ic A(H1N1) vaccine in pregnant women who had received prior seasonal influenza vaccine
and suggested that the potential interference between pH1N1 and seasonal vaccination
needed additional investigation [15]. Schlaudecker et al. directly compared immunogenici-
ty of inactivated influenza vaccine in pregnant versus nonpregnant women and found that
pregnancy modified antibody responses to the vaccine [134]. They demonstrated a signifi-
cantly decreased postimmunization HAI geometric mean titer and a nonsignificantly de-
creased geometric mean ratio (fold increase) to influenza A antigens after influenza
vaccine, even though overall seroconversion and seroprotection rates were comparable be-
tween the two groups of women. In a 2013 blinded randomized control study, Bischoff et
al. found that the immune response to an adjuvanted pandemic A(H1N1) vaccine in preg-
nant women was decreased compared with nonpregnant women [133]. Sperling et al. ex-
amined HAI titers over pregnancy and found that timing of vaccination did not alter
response, although there was a trend toward lower responses during the first trimester and
six weeks postpartum [135].
A small study of 36 women during the 2012–2014 flu seasons suggests that T-follicular helper
(Tfh) cell response to vaccination was highest during the first trimester of pregnancy. Tfh cells
are required for the generation of high-quality antibody-producing B cells. Their expansion
has been shown to be a predictor of response to influenza vaccination outside of pregnancy
suggesting that immunologic changes during pregnancy may impact vaccine response.
Notably, there was no significant expansion of Tfh after vaccination during either the second
or third trimester [136].
In a study aimed to determine the optimal timing for vaccination within the second or
third trimesters of pregnancy, Yamaguchi et al. reported that serum antibody levels in vac-
cinated women depended not on gestational stage but on the amount of time elapsed, since
vaccination antibody titers decreased with time [110]. This observation is supported by oth-
er studies documenting that influenza-specific antibodies after vaccination are typically
short lived [115].
Two separate studies of vaccine effectiveness in nonpregnant adults during the 2011–2012
influenza season also suggest that vaccine effectiveness wanes with time since vaccination
[137, 138]. In both of these studies, vaccination effectiveness waned in people who were
vaccinated 93 days—around 3 months—or more before presentation of symptoms. A similar
observation was made by Fisher et al. who demonstrated a significant linear decline over time
in HAI titers after pH1N1 infection or vaccination (p = 0.04 for infected and p = 0.009 for
vaccinated) [115].
Taken together, these observations support a consensus that pregnant women are capable
of mounting a robust immune response to influenza vaccination during the second and
third trimester of pregnancy. Experimental evidence during the first trimester is less clear,
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due in part to a limited number of studies on influenza vaccination during the first trimes-
ter.
There is increasing evidence suggesting that—regardless of initial vaccine response—the level
of vaccine-mediated anti-influenza-specific antibodies decreases with time. This waning of
antibody implies that women vaccinated during the first trimester of pregnancy might be less
well protected as their pregnancy progresses. It is well documented that serious influenza-
related morbidity in healthy pregnant women most often occurs during the second and third
trimester of pregnancy. So a reasonable goal appears to be ensuring the highest possible level
of protection during the second and third trimesters. Studies on waning immunity suggest
that this may be precisely opposite of what occurs in women who are vaccinated early in
pregnancy; protection wanes as risk increases.
6.1. Timing maternal vaccination for protection of neonates
Cross-placental transfer of immunity occurs when antibodies cross the placenta via active
transport, particularly in the final weeks of pregnancy. It is logical to assume that vaccine-
induced maternal antibody transmitted to the fetus will provide protection to the infant during
the first months of life, and several studies document increased antibody titers in infants of
vaccinated mothers [120].
Comparable to studies of vaccinated mothers, researchers have demonstrated that the titers of
influenza-specific antibodies in newborns, while not affected by trimester of maternal vacci-
nation (within second or third trimester), do wane with time and are short lived [75]. Tsatsaris
et al. also noted a trend toward lower cord blood antibody titer associated with longer intervals
between maternal vaccination and delivery. A similar observation was made by Yamaguchi et
al. who reported that transfer rate from the maternal blood to the fetal blood at time of delivery
tended to be inversely correlated with duration of gestation postvaccination [110]. Some
additional studies have hinted at lower cord blood titers among infants of women vaccinated
in the first trimesters, but it is unclear if this is clinically significant [131].
Taken together, these studies serve to highlight the complicated nature of immunity particu-
larly during pregnancy in response to vaccination and invite further virological and epide-
miological studies to confirm and fully understand these observations and to correlate changes
in antibody titer with clinical outcomes in both mothers and infants. As our understanding
evolves, we may need to develop a more nuanced approach—one that takes into consideration
the trimester of exposure to both circulating virus and vaccines—to optimize vaccine effec-
tiveness during the period of highest risk of influenza disease.
The recommendation to vaccinate all pregnant women regardless of gestational age is
motivated in part by operational concerns. Timing of the influenza vaccine campaigns occurs
in the fall in temperate regions. Pregnancy, on the other hand, occurs throughout the year. Since
pregnancy presents a period of regularly scheduled and repeat visits, a more tailored approach
to influenza vaccine coverage may be appropriate in order to stack the odds in favor of the
highest level of protection for both mother and infant.
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7. Conclusions
The impact of influenza infection on pregnant women and newborns is well documented. The
increased risk for morbidity and mortality has resulted in the universal recommendation that
pregnant women be vaccinated for influenza at any stage of pregnancy [65]. Evidence to date
suggests that influenza vaccination during pregnancy is similarly effective as in the nonpreg-
nant population. Pregnant women mount robust immune response that correlates with clinical
efficacy. This immunity then is transferred to the fetus during gestation, providing clinical
benefit to infants less than 6 months of age. And while not a component of this review, there
is substantial evidence that influenza vaccines are safe during all stages of pregnancy with no
evidence of risk of adverse pregnancy outcome linked to influenza vaccines [3, 65, 131, 139,
140].
Gaps remain in our understanding of influenza risk over all seasons and trimesters, of ma-
ternal immunity, and of optimal timing of vaccination. To this end, in January of 2015, the
Bill and Melinda Gates Foundation held a meeting of global stakeholders in the maternal
influenza field. Participants identified a need for stronger evidence regarding, among oth-
er issues, the burden of disease and maternal immunization efficacy [141]. Expanding this
evidence base will allow for a deeper understanding of influenza in this population and
the development of more robust and efficacious public health approaches toward this dis-
ease.
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